This page is dedicated to news and information about CTD Holding’s therapies for use in Niemann-Pick Disease Types C (NPC). Information is released as it becomes available.
About CTD Holdings:
CTD Holdings, Inc. is focused on the use of cyclodextrins in drug development in treatment for Niemann-Pick Disease Type C (NPC). The mission of CTD Holdings Inc. is to develop, manufacture, and distribute cyclodextrin-based high value products. Their products treat disease, improve quality of life, and provide solutions in a broad range of applications including pharmaceutical formulation, medical diagnostics, cosmetics, nutraceuticals, and nutrition. For more information, please visit CTDHoldings.com.
CTD Holdings Presents Compassionate Use Data
on Trappsol(R) Cyclo(TM) to Treat
Niemann-Pick Disease Type C and Provides Update
on Progress of U.S. and EU Clinical Trials at
13th Annual WORLDSymposium
CTD Holdings Files Clinical Trial Application
with Italian Drug Agency to Continue Advancing
Trappsol(R) Cyclo(TM) Drug Development Program
to Treat Niemann-Pick Disease Type C
CTD HOLDINGS IV TRAPPSOL CYCLO STUDY
The NNPDF Central Office has received notice that
CTD’s US trial parameters for the IV Trappsol Cyclo study in NPC
are now published at Clinical Trials.Gov.
CTD HOLDINGS PRESS RELEASE
CTD Holdings Announces MHRA Approval of Clinical Trial
Application for Treatment of NPC With Trappsol(R) Cyclo(TM)